📣 VC round data is live. Check it out!
- Public Comps
- QuidelOrtho
QuidelOrtho Valuation Multiples
Discover revenue and EBITDA valuation multiples for QuidelOrtho and similar public comparables like SS Innovations, PHC Holdings, MedicalSystem Technology, Advanced Medical Solutions Group and more.
QuidelOrtho Overview
About QuidelOrtho
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Founded
1987
HQ

Employees
6.5K
Website
Financials (LTM)
EV
$4B
Valuation Multiples
Start free trialQuidelOrtho Financials
QuidelOrtho reported last 12-month revenue of $3B and EBITDA of $607M.
In the same LTM period, QuidelOrtho generated $1B in gross profit, $607M in EBITDA, and $137M in net income.
Revenue (LTM)
QuidelOrtho P&L
In the most recent fiscal year, QuidelOrtho reported revenue of $3B and EBITDA of $597M.
QuidelOrtho is profitable as of last fiscal year, with gross margin of 47%, EBITDA margin of 22%, and net margin of 5%.
Financial data powered by Morningstar, Inc.
QuidelOrtho Stock Performance
QuidelOrtho has current market cap of $777M, and enterprise value of $4B.
Market Cap Evolution
QuidelOrtho's stock price is $11.39.
QuidelOrtho share price decreased by 7.3% in the last 30 days, and by 62.9% in the last year.
QuidelOrtho has an EPS (earnings per share) of $2.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $777M | 3.0% | -7.3% | -49.9% | -62.9% | $2.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialQuidelOrtho Valuation Multiples
QuidelOrtho trades at 1.3x EV/Revenue multiple, and 5.8x EV/EBITDA.
EV / Revenue (LTM)
QuidelOrtho Financial Valuation Multiples
As of May 15, 2026, QuidelOrtho has market cap of $777M and EV of $4B.
QuidelOrtho has a P/E ratio of 5.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified QuidelOrtho Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


QuidelOrtho Margins & Growth Rates
QuidelOrtho grew revenue by 0% and EBITDA by 5% in the last fiscal year.
In the most recent fiscal year, QuidelOrtho reported gross margin of 47%, EBITDA margin of 22%, and net margin of 5%.
QuidelOrtho Margins
QuidelOrtho Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
QuidelOrtho Operational KPIs
QuidelOrtho's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
QuidelOrtho's Rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
QuidelOrtho's Rule of X is 23% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
QuidelOrtho Competitors
QuidelOrtho competitors include SS Innovations, PHC Holdings, MedicalSystem Technology, Advanced Medical Solutions Group, Nanosonics, Bioventus, Anteris Technologies US, InMode, ChemoMetec and Barco.
Most QuidelOrtho public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 18.5x | — | (131.6x) | — | |||
| 0.9x | 0.9x | 6.2x | 6.2x | |||
| 15.6x | 14.1x | 52.6x | 62.3x | |||
| 3.4x | 2.6x | 20.4x | 11.7x | |||
| 4.2x | 4.1x | 26.6x | 35.9x | |||
| 1.7x | 1.6x | 8.2x | 8.1x | |||
| 223.1x | 100.7x | (4.8x) | (4.4x) | |||
| 0.9x | 0.9x | 3.3x | 3.6x | |||
This data is available for Pro users. Sign up to see all QuidelOrtho competitors and their valuation data. Start Free Trial | ||||||
QuidelOrtho M&A Activity
QuidelOrtho has acquired 5 companies to date.
Last acquisition by QuidelOrtho was on April 19th 2026. QuidelOrtho acquired LEX Diagnostics for $100M (EV/Revenue multiple of ).
Latest Acquisitions by QuidelOrtho
| Description | LEX Diagnostics develops medical devices for molecular diagnostics in primary care, emphasizing nasal and oral samples for viral pathogens. A 2020 spin-out from TTP plc based in Melbourn, UK, the company reduced PCR testing time, cost, and device size through internal R&D. | Ortho-Clinical Diagnostics is a Rochester-based provider of in vitro diagnostic solutions for clinical laboratories, hospitals, blood banks, and transfusion centers worldwide. Products include analyzers like VITROS systems for immunoassay, clinical chemistry, and infectious disease testing, alongside blood typing reagents and automation platforms. Acquired by Carlyle Group in 2016, the company supports over 1,000,000 tests daily through its high-throughput platforms. | Alere Triage unit is a diagnostics platform featuring the Triage MeterPro system for point-of-care testing of cardiac biomarkers, BNP levels, and toxicology panels. Integrated with Beckman Coulter analyzers, it delivers quantitative results in 15-20 minutes from fingerstick samples. Deployed in over 10,000 U.S. emergency departments, the assets support rapid diagnosis of heart failure and drugs-of-abuse screening. Acquired by Abbott in 2017 as part of Alere, the platform processes millions of tests annually worldwide. | RPS Diagnostics develops InflammaDry and AdenoPlus, point-of-care tests for eye conditions using lateral-flow technology. InflammaDry detects MMP-9 for dry eye inflammation, while AdenoPlus identifies viral versus bacterial conjunctivitis. Both FDA-cleared, CLIA-waived, and CE-marked products integrate with Quidel's diagnostic portfolio post-acquisition, with manufacturing shifted to San Diego. Eye care professionals use these 10-minute tests in clinics for rapid diagnosis and treatment guidance. | |
| HQ Country | |||||
| HQ City | Cambridge | Raritan, NJ | Boston, MA | Sarasota, FL | |
| Deal Date | 19 Apr 2026 | 23 Dec 2021 | 17 Jul 2017 | 16 May 2017 | |
| Valuation | $100M | $6B | $440M | $14M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all QuidelOrtho acquisitions and their M&A valuation multiples. Start Free Trial | |||||
QuidelOrtho Investment Activity
QuidelOrtho has invested in 1 company to date.
Latest investment by QuidelOrtho was on August 17th 2023. QuidelOrtho invested in Dendi in their $2M Seed round (EV/Revenue multiple of ).
Latest Investments by QuidelOrtho
| Description | Dendi is a provider of cloud-based laboratory information management systems for clinical diagnostics. The U.S.-headquartered company offers LIMS software with integration for analyzers, workflow automation, and compliance with CLIA and HIPAA standards, serving pathology labs and reference laboratories. | Dendi is a provider of cloud-based laboratory information management systems for clinical diagnostics. The U.S.-headquartered company offers LIMS software with integration for analyzers, workflow automation, and compliance with CLIA and HIPAA standards, serving pathology labs and reference laboratories. |
| HQ Country | ||
| HQ City | Durham, NC | Durham, NC |
| Deal Date | 17 Aug 2023 | 12 Aug 2022 |
| Round | Seed | Seed |
| Raised | $2M | $2M |
| Investors | QuidelOrtho | QuidelOrtho; Teamworthy Ventures; Triangle Tweener Fund |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all QuidelOrtho investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout QuidelOrtho
| When was QuidelOrtho founded? | QuidelOrtho was founded in 1987. |
| Where is QuidelOrtho headquartered? | QuidelOrtho is headquartered in United States. |
| How many employees does QuidelOrtho have? | As of today, QuidelOrtho has over 6K employees. |
| Who is the CEO of QuidelOrtho? | QuidelOrtho's CEO is Brian J. Blaser. |
| Is QuidelOrtho publicly listed? | Yes, QuidelOrtho is a public company listed on Nasdaq. |
| What is the stock symbol of QuidelOrtho? | QuidelOrtho trades under QDEL ticker. |
| When did QuidelOrtho go public? | QuidelOrtho went public in 1981. |
| Who are competitors of QuidelOrtho? | QuidelOrtho main competitors include SS Innovations, PHC Holdings, MedicalSystem Technology, Advanced Medical Solutions Group, Nanosonics, Bioventus, Anteris Technologies US, InMode, ChemoMetec, Barco. |
| What is the current market cap of QuidelOrtho? | QuidelOrtho's current market cap is $777M. |
| What is the current revenue of QuidelOrtho? | QuidelOrtho's last 12 months revenue is $3B. |
| What is the current revenue growth of QuidelOrtho? | QuidelOrtho revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of QuidelOrtho? | Current revenue multiple of QuidelOrtho is 1.3x. |
| Is QuidelOrtho profitable? | Yes, QuidelOrtho is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of QuidelOrtho? | QuidelOrtho's last 12 months EBITDA is $607M. |
| What is QuidelOrtho's EBITDA margin? | QuidelOrtho's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of QuidelOrtho? | Current EBITDA multiple of QuidelOrtho is 5.8x. |
| What is the current FCF of QuidelOrtho? | QuidelOrtho's last 12 months FCF is $91M. |
| What is QuidelOrtho's FCF margin? | QuidelOrtho's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of QuidelOrtho? | Current FCF multiple of QuidelOrtho is 38.5x. |
| How many companies QuidelOrtho has acquired to date? | As of May 2026, QuidelOrtho has acquired 5 companies. |
| What was the largest acquisition by QuidelOrtho? | $6B acquisition of Ortho-Clinical Diagnostics on 23rd December 2021 was the largest M&A QuidelOrtho has done to date. |
| What companies QuidelOrtho acquired? | QuidelOrtho acquired Ortho-Clinical Diagnostics, Alere (Triage unit), LEX Diagnostics, RPS Diagnostics (InflammaDry and AdenoPlus diagnostic units), and Immutopics. |
| In how many companies QuidelOrtho has invested to date? | As of May 2026, QuidelOrtho has invested in 1 company. |
| What was the last QuidelOrtho investment? | On 17th August 2023 QuidelOrtho invested in Dendi, participating in a $2M Seed round. |
| In what companies QuidelOrtho invested in? | QuidelOrtho invested in Dendi. |
See public comps similar to QuidelOrtho
Lists including QuidelOrtho
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

